Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Cancer (NASDAQ: XAIR) reported interim Phase 1 UNO data showing early clinical activity and a favorable safety profile after a single intratumoral injection in ten heavily pretreated patients with cutaneous or subcutaneous tumors.
Key points: two triple negative breast cancer patients show no evidence of disease, seven patients alive 19–37 months post‑treatment, most adverse events Grade 1, one treatment‑related serious hypoxia event that resolved.
Beyond Air (NASDAQ: XAIR) announced that CEO Steve Lisi will participate in the 38th Annual Roth Conference in Laguna Niguel, CA, March 22–24, 2026.
Steve Lisi will appear for a fireside chat and one-on-one meetings on Monday, March 23 at 8:00am PT. A live webcast is available and an archive will be posted for 90 days after the event. Investors seeking a one-on-one should contact their bank representative to request a meeting.
Beyond Air (NASDAQ: XAIR) announced that the previously disclosed proposed sale of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd. will not proceed. A January 2026 letter of intent expired on March 9, 2026 and the parties did not execute a definitive agreement.
The company said it will retain its interest in NeuroNOS, continue to evaluate strategic alternatives for the NeuroNOS platform, and remain focused on advancing its core nitric oxide platform and LungFit programs.
Beyond Air (NASDAQ: XAIR) commented on a landmark independent review published Feb 2026 that synthesizes data from 27 studies on high‑dose inhaled nitric oxide (iNO) delivered well above the FDA‑approved 20 ppm. The review highlights multimodal antimicrobial activity, potential in pneumonia, NTM, bronchiolitis, COVID‑19, and a roadmap for future research.
Beyond Air noted the review reinforces momentum behind its clinical programs and could accelerate development of high‑dose iNO as a novel respiratory antimicrobial.
Beyond Air (NASDAQ: XAIR) reported fiscal Q3 2026 results with revenue up 105% YoY to $2.2M, gross profit of $0.3M, and net loss of $7.3M (‑$0.85/sh). Pro forma cash totaled $22.3M, including $4.5M net PIPE proceeds, which the company says funds operations into calendar 2027. The company maintained FY2026 revenue guidance of $8–10M and announced a binding LOI for NeuroNOS consideration up to $32.5M plus 19.99% equity in XTL.
Beyond Cancer (NASDAQ: XAIR) was selected to present Phase 1 data on intratumoral ultra-high concentration nitric oxide (UNO) in solid tumor metastases at the AACR Annual Meeting 2026 in San Diego.
The abstract will be presented April 19, 2026 (Poster Section 13, Poster Board 22, Poster Number 304) and the itinerary text is scheduled for online publication March 17, 2026 at 4:30 PM ET.
Beyond Air (NASDAQ: XAIR) said Steve Lisi, Chairman & CEO, will participate in two investor conferences in early February 2026: the Noble Capital Markets Emerging Growth Virtual Equity Conference (Feb 4–5) and the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Feb 9–11) in Snowbird, UT.
The Noble event includes a corporate presentation on Feb 5 at 2:00 PM ET plus one-on-one meetings; the presentation will be webcast live and archived on the company website for 90 days following the event. BTIG participation is scheduled as one-on-one meetings.
Beyond Air (NASDAQ: XAIR) will report third fiscal quarter 2026 financial results for the period ended December 31, 2025 on Friday, February 13, 2026. Management will host a conference call and webcast at 8:00 AM Eastern Time the same day. Investors can join by dialing the domestic number 1-877-407-0784 or the international number 1-201-689-8560 using Conference ID 13758405. A live webcast will be available via the company’s Events page, and an online replay will be posted about one hour after the call.
Beyond Air (NASDAQ: XAIR) entered a private placement agreement to sell 3,930,818 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,930,818 shares at a combined purchase price of $1.272 per share/associated warrant, for expected gross proceeds of approximately $5.0 million before fees.
The issued warrants will have an exercise price of $1.147, be exercisable immediately, and expire five years from issuance. Closing is expected on or about January 16, 2026, subject to customary conditions. Rodman & Renshaw is the exclusive placement agent; Roth Capital Partners and D. Boral Capital are financial advisors. Net proceeds will be used for working capital and general corporate purposes.
XTL Biopharmaceuticals (NASDAQ:XTLB) agreed on Jan. 13, 2026 to acquire 85% of NeuroNOS from Beyond Air (NASDAQ:XAIR) to build a disease‑modifying autism and neuro‑oncology platform. Transaction consideration includes 19.9% of XTL share capital to Beyond Air, $1.0M cash, and up to $32.5M in milestone payments (development and commercial). NeuroNOS holds FDA Orphan Drug designations for Phelan‑McDermid Syndrome and glioblastoma. Leadership includes founder Prof. Haitham Amal and two Nobel laureates. The release cites autism prevalence of 1 in 31 U.S. children and notes a $50M NIH allocation for autism research.